¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29
±³À°ÀÏÀÚ : 2018-07-29
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø µ¿°ü 6Ãþ ´ë°­´ç  
±³À°ÁÖÁ¦ : KGOG 2018 Summer Workshop Uterine Cancer      
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 10,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07¿ù 29ÀÏ  08:55~09:00 Orientation  ÀÌÁ¾¹Î(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 07¿ù 29ÀÏ  09:00~09:20 TCGA genomic classification of endometrial cancer  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  09:20~09:40 Current clinical guidelines and review of background trials  À̱¤¹ü(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  09:40~10:00 Future perspective and novel treatment  ÁÖ¿ø´ö(Â÷ÀÇ°ú´ëÇÐ) 
Åä·Ð 07¿ù 29ÀÏ  10:00~10:10 Discussion  () 
±³À°½Ã°£ 07¿ù 29ÀÏ  10:30~10:50 Molecular profiles of non-endometrioid endometrial cancer  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  10:50~11:10 Current clinical guidelines and review of background trials  ¹Ú»óÀÏ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø) 
±³À°½Ã°£ 07¿ù 29ÀÏ  11:10~11:30 Future perspective and novel treatment  ±èÈñ½Â(¼­¿ïÀÇ´ë) 
Åä·Ð 07¿ù 29ÀÏ  11:30~11:40 Discussion  () 
±³À°½Ã°£ 07¿ù 29ÀÏ  11:40~12:00 Preoperative assessment for the risk of uterine sarcoma  À̹æÇö(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  12:00~12:20 Optimal adjuvant treatment according to sarcoma subtype  ÀÌ¿ø¹«(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  12:20~12:40 Strategy in combination of targeted therapy in advanced, recurrent uterine sarcoma  ±èÁø¿µ(°è¸íÀÇ´ë) 
Åä·Ð 07¿ù 29ÀÏ  12:40~12:50 Discussion  () 
±³À°½Ã°£ 07¿ù 29ÀÏ  13:50~14:10 Sentinel node biopsy : Current status and upcoming KGOG study  ±è´ë¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  14:10~14:40 Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)  Hidemichi Watari(Hokkaido University Hospital) 
Åä·Ð 07¿ù 29ÀÏ  14:40~14:50 Discussion  () 
±³À°½Ã°£ 07¿ù 29ÀÏ  14:50~15:10 History and guidelines for management of Lynch syndrome  ±è¹Î±Ô(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  15:10~15:30 Current status in managing hereditary colorectal cancer  ±è´ö¿ì(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07¿ù 29ÀÏ  15:30~15:50 Future perspective for hereditary endometrial cancer  ÃÖ¹Îö(Â÷ÀÇ°ú´ëÇÐ) 
Åä·Ð 07¿ù 29ÀÏ  15:50~16:00 Discussion  () 
±³À°½Ã°£ 07¿ù 29ÀÏ  16:20~17:20 Recent precision medicine in recurrent ovarian cancer -how to maximize patient treatment outcome-  ¹ÌÁ¤() 
Åä·Ð 07¿ù 29ÀÏ  17:20~17:30 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø ¿µ»óȹµæÀÇ ±â¼úÀû Ãø¸é°ú Æó¾Ï °ËÁø : 2018-07-29
´ÙÀ½±Û ´ëÇÑ¿µ»óÀÇÇÐȸ »ó±ÙÀÇ»ç À¯¹æÃÔ¿µ¿ëÀåÄ¡ Ç°Áú°ü¸® ±³À° 3ÀÏÂ÷(7¿ù29ÀÏ) : 2018-07-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 124 2024-05-28
20896 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 208 2024-05-28
20895 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 163 2024-05-28
20894 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 71 2024-05-28
20893 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 91 2024-05-28
20892 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 52 2024-05-28
20891 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 83 2024-05-28
20890 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 183 2024-05-27
20889 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 118 2024-05-27
20888 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 250 2024-05-27
20887 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 118 2024-05-27
20886 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 57 2024-05-27
20885 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 57 2024-05-27
20884 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 98 2024-05-27
20883 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 92 2024-05-27
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷